Nanobiotix
Research Nanobiotix (NBTX) on Bullrun: market cap USD 1.19B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNBTX
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.19B
- Financial periodFY2025
- RevenueEUR 29.64M
- Revenue growth355.3%
- Net income-EUR 23.96M
- Free cash flow-EUR 33.97M
- Gross margin109.9%
Valuation Snapshot
latest market cap is USD 1.19B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 29.64M | -EUR 23.96M | -EUR 33.97M | 109.9% | -0.5 | EUR 52.75M | EUR 95.32M | -EUR 84.48M |
| FY2024 | -EUR 11.61M | -EUR 68.13M | -EUR 20.40M | 61.9% | -1.44 | EUR 49.74M | EUR 50.90M | -EUR 65.70M |
| FY2023 | EUR 30.06M | -EUR 39.70M | -EUR 12.81M | 120.5% | -1.08 | EUR 75.28M | EUR 50.57M | -EUR 1.84M |
| FY2022 | EUR 0 | -EUR 57.04M | -EUR 37.20M | n/a | -1.64 | EUR 41.39M | EUR 53.17M | -EUR 27.05M |
| FY2021 | EUR 10.00K | -EUR 47.00M | -EUR 30.11M | 26500.0% | -1.35 | EUR 83.92M | EUR 46.02M | EUR 26.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 1.19B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.12B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 136.05M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 342.97M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 127.93M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 282.09M | n/a | n/a | n/a |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nanobiotix's market cap?
Nanobiotix's market capitalization is USD 1.19B.
What does Nanobiotix do?
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A.